SYRE
Spyre Therapeutics, Inc.
$80.79
+0.02%
$7.0B
No data for this timeframe.
Vol
Market Cap$7.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (96%)
Inst. Holders50 funds
Inst. Value$2.4B
Inst. Activity15 buys / 6 sells
Insider Activity0B / 12S
Insider Net $-$5.5M
SEC Reports14
Press Releases4
Recent Activity
Jun 12, 2026
SEC
A major institutional cluster reveals 13 net buyers vs 3 net sellers in SYRE during Q3 2024, with aggregate buying of $8
INST-CLUSTER — Impact 6/10
Jun 11, 2026
SEC
Four mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity) collectively added $468.9M in SY
INST-CLUSTER — Impact 3/10
Jun 11, 2026
short_volume
Short Volume: SYRE — 56.4% short (0.4M / 0.6M)
Short: 354,066 | Exempt: 101 | TRF Vol: 627,550 | Short Ratio: 56.4% | Off-exchange volume (dark poo
Jun 4, 2026
SEC
CEO Turtle Cameron and CFO Scott Burrows sold a combined $372K in SYRE stock on June 1, 2026, at ~$69.40-$69.75. The CFO
CLUSTER — Impact 2/10
Jun 3, 2026
Insider
Sloan Sheldon sold 8,333 shares
Chief Medical Officer @ $75.00 ($625.0K)
Jun 3, 2026
Insider
Sloan Sheldon acquired via exercise 8,333 shares
Chief Medical Officer @ $27.46 ($228.8K)
Jun 1, 2026
Insider
Turtle Cameron sold 3,557 shares
Chief Executive Officer @ $69.40 ($246.9K)
Inst.
Capital International Investors — TRIM
1,746,129 shares ($88.1M)
Price Targets
$96.07
+18.9% upside
Buy
Current $80.79
Low $78.00
Median $95.00
High $115.00
15 analysts
$78.00
$115.00
Analyst Ratings
12Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | Deutsche Bank | MAINTAIN | Buy → Buy |
| May 6, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| May 6, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Apr 17, 2026 | Jones Trading | MAINTAIN | Buy → Buy |
| Apr 14, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.71 ▼ -2.0% | $-0.90 — $-0.49 | -45% YoY | 13 |
| Next Q | $-0.69 ▼ -2.7% | $-0.95 — $-0.51 | -362% YoY | 13 |
| Current FY | $-2.83 ▲ +1.7% | $-3.78 — $-2.29 | -43% YoY | 13 |
| Next FY | $-3.03 ▼ -2.1% | $-4.63 — $-1.61 | -7% YoY | 13 |
Latest Reports
BULLISH
INST-CLUSTER
6/10
A major institutional cluster reveals 13 net buyers vs 3 net sellers in SYRE during Q3 2024, with aggregate buying of $8
Jun 12, 2026
NEUTRAL
INST-CLUSTER
3/10
Four mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity) collectively added $468.9M in SY
Jun 11, 2026
NEUTRAL
Press
6/10
Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, raising approximate
Apr 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| FMR LLC | $594.2M | ADD |
| BlackRock, Inc. | $278.5M | ADD |
| RTW INVESTMENTS, LP | $210.4M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $154.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Sloan Sheldon | SELL | $625.0K |
| Jun 3, 2026 | Sloan Sheldon | M | $228.8K |
| Jun 1, 2026 | Turtle Cameron | SELL | $246.9K |
| Jun 1, 2026 | Burrows Scott | SELL | $125.6K |
| Jun 1, 2026 | Burrows Scott | M | $108.8K |
50 institutional holders with $2.4B total value (47,186,028 shares) as of 2026-Q1. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 15 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | FMR LLC | 11,781,024 | $594.2M | 25.0% | ADD +28.5% |
| 3 | BlackRock, Inc. | 5,521,221 | $278.5M | 11.7% | ADD +38.7% |
| 4 | RTW INVESTMENTS, LP | 4,171,996 | $210.4M | 8.8% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3,057,401 | $154.2M | 6.5% | — |
| 6 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2,790,785 | $140.8M | 5.9% | ADD +39.9% |
| 7 | STATE STREET CORP | 2,607,031 | $131.5M | 5.5% | ADD +26.8% |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 1,824,811 | $92.0M | 3.9% | — |
| 9 | Capital International Investors | 1,746,129 | $88.1M | 3.7% | TRIM -50.0% |
| 10 | JANUS HENDERSON GROUP PLC | 1,656,164 | $83.6M | 3.5% | DOUBLED +13969.3% |
| 11 | RA CAPITAL MANAGEMENT, L.P. | 1,621,620 | $81.8M | 3.4% | NEW |
| 12 | BANK OF AMERICA CORP /DE/ | 1,228,093 | $61.9M | 2.6% | DOUBLED +192.6% |
| 13 | BAKER BROS. ADVISORS LP | 1,000,000 | $50.4M | 2.1% | — |
| 14 | FRANKLIN RESOURCES INC | 882,833 | $44.5M | 1.9% | ADD +39.5% |
| 15 | Polar Capital Holdings Plc | 792,847 | $40.0M | 1.7% | — |
| 16 | Capital World Investors | 666,564 | $33.6M | 1.4% | DOUBLED +233.0% |
| 17 | VANGUARD PORTFOLIO MANAGEMENT LLC | 585,130 | $29.5M | 1.2% | — |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 562,653 | $28.4M | 1.2% | ADD +35.1% |
| 19 | Pictet Asset Management Holding SA | 491,649 | $24.8M | 1.0% | TRIM -46.2% |
| 20 | VANGUARD FIDUCIARY TRUST CO | 464,651 | $23.4M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Capital International Investors | TRIM | 3,492,541 | 1,746,129 | -50.0% | $88.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 419,727 | 1,228,093 | +192.6% | $61.9M | 2026-Q1 |
| Capital World Investors | DOUBLED | 200,172 | 666,564 | +233.0% | $33.6M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 913,960 | 491,649 | -46.2% | $24.8M | 2026-Q1 |
| Blackstone Inc. | TRIM | 500,998 | 292,847 | -41.5% | $14.8M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | ADD | 146,079 | 292,126 | +100.0% | $14.7M | 2026-Q1 |
| MORGAN STANLEY | ADD | 182,734 | 246,719 | +35.0% | $12.4M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | DOUBLED | 38,256 | 159,217 | +316.2% | $8.0M | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 37,871 | 87,065 | +129.9% | $4.4M | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 549 | 64,002 | +11557.9% | $3.2M | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 27,277 | 53,970 | +97.9% | $2.7M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 77,290 | 47,697 | -38.3% | $2.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 5,554 | 9,931 | +78.8% | $500.9K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 6,117 | 8,975 | +46.7% | $452.7K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 12,882 | 5,858 | -54.5% | $295.5K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 705 | 1,916 | +171.8% | $96.6K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 400 | 901 | +125.3% | $45.4K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 656 | 888 | +35.4% | $44.8K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 86 | 123 | +43.0% | $6.2K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 58 | 117 | +101.7% | $5.9K | 2026-Q1 |
| Point72 Asset Management, L.P. | EXIT | 662,351 | 0 | -100.0% | $0.00 | 2026-Q1 |
| FMR LLC | ADD | 9,060,144 | 11,638,819 | +28.5% | $381.3M | 2025-Q4 |
| BlackRock, Inc. | ADD | 3,982,744 | 5,522,101 | +38.7% | $180.9M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 3,050,730 | 4,035,074 | +32.3% | $132.2M | 2025-Q4 |
| Capital International Investors | ADD | 2,392,541 | 3,492,541 | +46.0% | $114.4M | 2025-Q4 |
9 unique insiders with 25 transactions. Net insider value: -$5.5M ($0.00 bought, $5.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Sloan Sheldon | Chief Medical Officer | SELL | 8,333 | $75.00 | $625.0K |
| Jun 3, 2026 | Sloan Sheldon | Chief Medical Officer | EXERCISE | 8,333 | $27.46 | $228.8K |
| Jun 1, 2026 | Turtle Cameron | Chief Executive Officer | SELL | 3,557 | $69.40 | $246.9K |
| Jun 1, 2026 | Burrows Scott L | Chief Financial Officer | SELL | 1,801 | $69.75 | $125.6K |
| Jun 1, 2026 | Burrows Scott L | Chief Financial Officer | EXERCISE | 7,500 | $14.50 | $108.8K |
| May 27, 2026 | Fairmount Funds Management LLC | Director | AWARD | 8,026 | — | — |
| May 27, 2026 | Albers Jeffrey W. | Director | AWARD | 8,026 | — | — |
| May 27, 2026 | HENDERSON MICHAEL THOMAS | Director | AWARD | 8,026 | — | — |
| May 27, 2026 | Stelzer Laurie | Director | AWARD | 8,026 | — | — |
| May 27, 2026 | McKenna Mark C. | Director | AWARD | 8,026 | — | — |
| May 27, 2026 | Milligan Sandra | Director | AWARD | 8,026 | — | — |
| May 8, 2026 | HENDERSON MICHAEL THOMAS | Director | SELL | 2,404 | $72.57 | $174.5K |
| May 1, 2026 | Turtle Cameron | Chief Executive Officer | SELL | 5,300 | $69.54 | $368.6K |
| May 1, 2026 | Sloan Sheldon | Chief Medical Officer | EXERCISE | 78,333 | $27.46 | $2.2M |
| May 1, 2026 | Sloan Sheldon | Chief Medical Officer | SELL | 21,306 | $69.53 | $1.5M |
| May 1, 2026 | Burrows Scott L | Chief Financial Officer | EXERCISE | 12,500 | $14.50 | $181.3K |
| May 1, 2026 | Burrows Scott L | Chief Financial Officer | SELL | 12,500 | $71.37 | $892.1K |
| Apr 1, 2026 | Burrows Scott L | Chief Financial Officer | EXERCISE | 7,500 | $14.50 | $108.8K |
| Apr 1, 2026 | Burrows Scott L | Chief Financial Officer | SELL | 6,200 | $49.21 | $305.1K |
| Apr 1, 2026 | Sloan Sheldon | Chief Medical Officer | EXERCISE | 7,958 | $21.66 | $172.4K |
| Apr 1, 2026 | Sloan Sheldon | Chief Medical Officer | SELL | 7,958 | $50.00 | $397.9K |
| Apr 1, 2026 | Turtle Cameron | Chief Executive Officer | SELL | 12,344 | $49.20 | $607.3K |
| Mar 3, 2026 | Burrows Scott L | Chief Financial Officer | EXERCISE | 2,500 | $14.50 | $36.3K |
| Mar 2, 2026 | Turtle Cameron | Chief Executive Officer | SELL | 5,900 | $41.73 | $246.2K |
| Feb 2, 2026 | Turtle Cameron | Chief Executive Officer | SELL | 957 | $31.82 | $30.5K |
14 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 1 mixed, 8 neutral. Avg impact: 4.6/10.
BULLISH
INST-CLUSTER
6/10
A major institutional cluster reveals 13 net buyers vs 3 net sellers in SYRE during Q3 2024, with ag
Jun 12, 2026
NEUTRAL
INST-CLUSTER
3/10
Four mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity) collectively
Jun 11, 2026
NEUTRAL
CLUSTER
2/10
CEO Turtle Cameron and CFO Scott Burrows sold a combined $372K in SYRE stock on June 1, 2026, at ~$6
Jun 4, 2026
BULLISH
8-K
7/10
Spyre Therapeutics expanded its license agreement with Paragon Therapeutics, removing the previous r
Jun 1, 2026
NEUTRAL
8-K
3/10
Spyre Therapeutics held its 2026 Annual Meeting on May 27, 2026, where stockholders approved the ame
May 29, 2026
NEUTRAL
CLUSTER
3/10
Four insiders at Spyre Therapeutics, including the CEO, CFO, and CMO, sold a total of $2.92M in open
May 9, 2026
MIXED
8-K
6/10
Spyre Therapeutics reported Q1 2026 financial results with a net loss of $69.0M ($0.74 per share), w
May 5, 2026
NEUTRAL
CLUSTER
2/10
CEO and CMO sold a combined $1.85M in open-market sales at ~$69.50, representing 0.027% of Spyre's $
May 2, 2026
BULLISH
424B5
8/10
Spyre Therapeutics is raising $300 million through a common stock offering, following positive Phase
Apr 13, 2026
NEUTRAL
8-K
5/10
Spyre Therapeutics reported preliminary cash of $741M as of March 31, 2026, including $30M from lega
Apr 13, 2026
BULLISH
8-K
7/10
Spyre Therapeutics announced positive Phase 2 topline data for SPY001 in ulcerative colitis, showing
Apr 13, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 10, 2026
BEARISH
CLUSTER
6/10
Two key executives at Spyre Therapeutics — the CFO and CMO — sold a combined $703K in open-market tr
Apr 4, 2026
NEUTRAL
EFFECT
3/10
Spyre Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to issu
Mar 2, 2026
NEUTRAL
6/10
Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share,
Apr 15, 2026
BEARISH
7/10
Spyre Therapeutics announced a $300 million public offering of common stock, with underwriters expec
Apr 13, 2026
BULLISH
8/10
Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE tria
Apr 13, 2026
NEUTRAL
3/10
Spyre Therapeutics granted stock options to purchase 70,200 shares to five non-executive employees a
Apr 3, 2026
Current analyst consensus: Strong Buy (96% buy). Based on 23 analysts: 12 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$96.07 mean target
+18.9% upside
Buy (1.00)
$78.00 Low
$115.00 High
| Metric | Value |
|---|---|
| Current Price | $80.79 |
| Target Low | $78.00 |
| Target Mean | $96.07 |
| Target Median | $95.00 |
| Target High | $115.00 |
| # Analysts | 15 |
| Recommendation | Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.71 | $-0.90 | $-0.49 | -45.0% | -2.0% | 4↑ 7↓ | $0.0B | 0.0% | 13 |
| Next Q 2026-09-30 |
$-0.69 | $-0.95 | $-0.51 | -361.5% | -2.7% | 6↑ 4↓ | $0.0B | 0.0% | 13 |
| Current FY 2026-12-31 |
$-2.83 | $-3.78 | $-2.29 | -43.0% | +1.7% | 4↑ 8↓ | $0.0B | 0.0% | 13 |
| Next FY 2027-12-31 |
$-3.03 | $-4.63 | $-1.61 | -7.1% | -2.1% | 5↑ 7↓ | $0.0B | 0.0% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.710 | |
| 7d ago | $-0.710 | |
| 30d ago | $-0.696 | -0.014 |
| 60d ago | $-0.701 | -0.009 |
| 90d ago | $-0.700 | -0.011 |
12 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | Deutsche Bank | MAINTAIN | Buy | Buy |
| May 6, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 6, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | Jones Trading | MAINTAIN | Buy | Buy |
| Apr 14, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 14, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | Raymond James | INITIATE | — | Strong Buy |
| Apr 14, 2026 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Apr 13, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 13, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Apr 13, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 18, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 20, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 16, 2026 | BTIG | REITERATE | Buy | Buy |
| Dec 18, 2025 | Mizuho | INITIATE | — | Outperform |
| Dec 17, 2025 | Citigroup | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 12 | 10 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 12 | 10 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 11 | 9 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 11 | 9 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 11 | 9 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 10 | 9 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
short_volume
Short Volume: SYRE — 56.4% short (0.4M / 0.6M)
Short: 354,066 | Exempt: 101 | TRF Vol: 627,550 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: SYRE — 81.8% short (0.7M / 0.8M)
Short: 659,603 | Exempt: 0 | TRF Vol: 806,125 | Short Ratio: 81.8% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
other
Spyre Therapeutics Announces Grants of Inducement Awards
<p>WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnol
Jun 3, 2026
fda
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
<p align="center"><em>Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete
May 26, 2026
other
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
<p>WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-
May 19, 2026
short_volume
Short Volume: SYRE — 63.0% short (0.4M / 0.7M)
Short: 413,443 | Exempt: 600 | TRF Vol: 655,809 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
SYRE Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
earnings
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class effica
May 4, 2026
short_interest
FTD: SYRE — 108,855 shares ($7.6M) failed to deliver
Settlement: 20260504, Price: $69.42, FTD Value: $7,556,714.1, SPYRE THERAPEUTICS, INC. COMMO
May 1, 2026
other
Spyre Therapeutics Announces Grants of Inducement Awards
<p>WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnolo
May 1, 2026
short_volume
Short Volume: SYRE — 57.1% short (0.3M / 0.5M)
Short: 289,880 | Exempt: 2,420 | TRF Vol: 507,602 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: SYRE — 74.3% short (0.6M / 0.8M)
Short: 630,483 | Exempt: 2,109 | TRF Vol: 848,887 | Short Ratio: 74.3% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: SYRE — 58.7% short (0.4M / 0.6M)
Short: 353,499 | Exempt: 16,678 | TRF Vol: 602,552 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_interest
FTD: SYRE — 123,621 shares ($8.6M) failed to deliver
Settlement: 20260417, Price: $69.70, FTD Value: $8,616,383.7, SPYRE THERAPEUTICS, INC. COMMO
Apr 16, 2026
offering
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
<p>WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechno